返回 
加入收藏
瑞舒伐他汀钙片联合芪参益气滴丸治疗慢性心力衰竭的临床观察
x
请在关注微信后，向客服人员索取文件
| 篇名： | 瑞舒伐他汀钙片联合芪参益气滴丸治疗慢性心力衰竭的临床观察 |
| TITLE： | |
| 摘要： | 目的：探讨瑞舒伐他汀钙片联合芪参益气滴丸治疗慢性心力衰竭的临床疗效、安全性及对患者心功能、炎症水平、氧化应激损伤的影响。方法：将2014年8月－2016年4月我院收治的90例慢性心力衰竭患者按随机数字表法分为观察组和对照组，各45例。对照组患者采用强心、利尿、扩血管等常规抗心力衰竭治疗，同时餐后0.5 h内口服芪参益气滴丸0.5 g，tid；观察组患者在对照组基础上睡前口服瑞舒伐他汀钙片20 mg，qd。比较两组患者治疗前后心功能、血清炎症因子、脑钠肽（BNP）、氧化应激水平，并观察两组患者临床疗效及不良反应发生情况。结果：治疗前，两组患者左心室射血分数（LVEF）、左心室收缩末期内径（LVESD）、左心室舒张末期内径（LVEDD）、肿瘤坏死因子α（TNF-α）、白细胞介素6（IL-6）、BNP、超氧化物歧化酶（SOD）、血清髓过氧化酶 （MPO）、基质金属蛋白酶9（MMP-9）水平比较，差异均无统计学意义（P＞0.05）；治疗后，两组患者LVEF显著升高，LVEDD、LVESD、TNF-α、IL-6、BNP显著降低，且观察组患者上述指标显著优于对照组，差异均有统计学意义（P＜0.05）；观察组患者MPO、MMP-9水平显著降低，SOD水平显著升高，且显著优于对照组，差异均有统计学意义（P＜0.05）；但对照组患者SOD、MPO、MMP-9水平与治疗前比较，差异无统计学意义（P＞0.05）。观察组患者治疗的临床有效率为97.8％，显著高于对照组的82.2％，差异有统计学意义（P＜0.05）。两组患者不良反应发生率比较，差异无统计学意义（P＞0.05）。结论：瑞舒伐他汀钙片联合芪参益气滴丸治疗慢性心力衰竭疗效显著，能有效降低患者炎症水平，减轻氧化应激损伤，延缓心室重构进程，改善心功能，且安全性较好。 |
| ABSTRACT： | OBJECTIVE： To investigate clinical efficacy and safety of Rosuvastatin calcium tablets combined with Qishen yiqi dripping pills in the treatment of chronic heart failure （CHF） and it effects on inflammatory level， oxidative stress injury and cardiac function of patients. METHODS： Ninety CHF patients in our hospital during Aug. 2014-Apr. 2016 were divided into observation group and control group according to random number table， with 45 cases in each group. Control group received routine anti-heart failure treatment as cardiac， diuretic， dilating vessel， and Qishen yiqi dripping pills orally 0.5 g， half an hour after meal， tid； observation group was additionally given Rosuvastatin calcium tablet orally 20 mg， at bedtime， qd， on the basis of control group. Cardiac function， serum inflammatory factor， BNP and oxidative stress levels were compared between 2 groups before and after treatment. Clinical efficacies and the occurrence of ADR were observed in 2 groups. RESULTS： Before treatment， there was no statistical significance in LVEF， LVESD， LVEDD， TNF-α， IL-6， BNP， SOD， MPO and MMP-9 levels between 2 groups （P＞0.05）. After treatment， LVEF of 2 groups were increased significantly， while LVEDD， LVESD， TNF-α and IL-6， BNP levels were decreased significantly； the above indexes of observation group was significantly better than those of control group， with statistical significance （P＜0.05）. MPO and MMP-9 of observation group were significantly decreased， while SOD level was significantly increased and better than that of control group， with statistical significance （P＜0.05）， but there was no statistical significance in SOD and MPO， MMP-9 levels of control group before and after treatment （P＞0.05）. The clinical response rate of observation group was 97.8％， which was significantly higher than 82.2％ of control group， with statistical significance （P＜0.05）. There was no statistical significance in the incidence of ADR between 2 groups （P＞0.05）. CONCLUSIONS： Rosuvastatin calcium tablets combined with Qishen yiqi dripping pills show significant therapeutic efficacy for CHF， can effectively reduce inflammatory level， relieve oxidant stress injury， delay the process of ventricular remodeling， and improve cardiac function with good safety. |
| 期刊： | 2017年第28卷第8期 |
| 作者： | 赵明昕，于霞，张晓非，李旭阳 |
| AUTHORS： | ZHAO Mingxin，YU Xia，ZHANG Xiaofei，LI Xuyang |
| 关键字： | 瑞舒伐他汀；芪参益气滴丸；慢性心力衰竭；心功能；炎症因子；氧化应激 |
| KEYWORDS： | Rosuvastatin； Qishen yiqi dripping pills； Chronic heart failure； Cardiac function； Inflammatory factor； Oxidative stress |
| 阅读数： | 1050 次 |
| 本月下载数： | 14 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
